Keros Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Keros Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue3.550.150.0020.100.00
Cost of Revenue0.00135.2687.2755.1433.86
Gross Profit3.55-135.11-87.2720.10-33.86
Operating Expenses
Research & Development173.63135.2687.2755.1433.86
Selling, General & Administrative40.7534.8327.5321.3312.80
Operating Expenses213.1534.83107.7176.4712.80
Operating Income-209.60-169.94-107.71-56.37-46.66
Other Income/Expense
Interest Income0.0014.763.640.030.00
Interest Expense0.000.000.000.00-0.01
Other Income/Expense22.542.403.030.361.13
Income
Income Before Tax-187.05-152.99-104.68-56.73-45.53
Income Tax Expense0.300.000.002.01-0.17
Net Income-187.35-152.99-104.68-58.74-45.36
Net Income - Continuous Operations-187.35-152.99-104.68-58.740.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-185.82-169.13-104.00-56.35-46.38
EBIT-187.05-169.94-104.68-56.73-46.66
Depreciation & Amortization1.230.820.670.400.28
Earnings Per Share
Basic EPS-5.00-5.00-4.00-3.00-3.00
Diluted EPS-5.00-5.00-4.00-3.00-3.00
Basic Shares Outstanding37.4429.4523.4423.3315.51
Diluted Shares Outstanding37.4429.4523.4423.3315.51